Review article: Optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - The role of epoetin, G-CSF and novel agents

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 9, 2010, Pages 929-937

  Mac Nicholas, R ^a   Norris, S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; ELTROMBOPAG; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERFERON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ERYTHROPOIETIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ABNORMAL LABORATORY RESULT; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTHRALGIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEPRESSION; DERMATITIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; INSOMNIA; INTERSTITIAL PNEUMONIA; IRRITABILITY; LEUKOCYTOCLASTIC VASCULITIS; LOW DRUG DOSE; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; POLYCYTHEMIA; PRIORITY JOURNAL; PRURITUS; PURE RED CELL ANEMIA; PUS; PYOGENIC INFECTION; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SIDE EFFECT; SPLEEN RUPTURE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG COMBINATION; HEPATITIS C, CHRONIC; VIROLOGY; VIRUS LOAD;

ANEMIA; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; NEUTROPENIA; POLYETHYLENE GLYCOLS; RIBAVIRIN; THROMBOCYTOPENIA; VIRAL LOAD; ERYTHROPOIETIN; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 77950554154     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04269.x     Document Type: Review

References (55)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965. (Pubitemid 32913521)
3. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 1069.
4. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652. (Pubitemid 37052151)
5. Thevenot T, Cadranel JF, Di Martino V, et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology 2007 45 : 377 383. (Pubitemid 46374594)
6. Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004 2 : 337 339. (Pubitemid 38447199)
7. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006 13 : 3351 3357. (Pubitemid 44669779)
8. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000 31 : 997 1004. (Pubitemid 30169949)
9. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002 123 : 141 151. (Pubitemid 34747535)
10. Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002 16 : 1633 1639.
11. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40 KD) plus ribavirin. Am J Gastroenterol 2008 103 : 1981 1988.
12. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004 19 : 1312 1317. (Pubitemid 39481767)
13. Siciliano M, Tomasella D, Milani A, Ricerca BM, Storti S, Rossi L. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology 1995 22 : 1132 1135.
14. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008 31 : 295 302. (Pubitemid 351890659)
15. Ma J, Ebben J, Xia H, et al. Hematocrit levels and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999 10 : 610 619. (Pubitemid 29117643)
16. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002 13 : 1928 1936.
17. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 339 : 584 590. (Pubitemid 28385655)
18. Collins A, Ma JZ, Ebben J, et al. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000 20 : 345 349.
19. Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999 33 : 1122 1130.
20. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006 44 : 491 498. (Pubitemid 43227873)
21. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004 40 : 1450 1458. (Pubitemid 39657021)
22. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
23. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 126 : 1015 1023. (Pubitemid 38451173)
24. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007 5 : 124 129.
25. Bain VG, Lee SS, Peltekian K, et al. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment Pharmacol Ther 2008 28 : 43 50. (Pubitemid 351782811)
26. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006 131 : 1040 1048. (Pubitemid 44515099)
27. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 361 : 580 593.
28. EASL. Final Results of Boceprevir Phase II HCV SPRINT-1 Study. EASL, 2009.
29. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007 46 : 371 379. (Pubitemid 47344771)
30. Costiniuk CT, Camacho F, Cooper CL. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death. Clin Infect Dis 2008 47 : 198 202. (Pubitemid 351920628)
31. Stravitz RT, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005 100 : 1415 1419. (Pubitemid 40904370)
32. Schecter JM, Mears JG, Alobeid B, Gaglio PJ. Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus. Liver Transpl 2007 13 : 1589 1592. (Pubitemid 350168202)
33. Leyland-Jones B, Semiglazov V, Pawlicki MJ, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Clin Oncol 2005 23 : 5960 5972. (Pubitemid 46300213)
34. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 18 : 362. (Pubitemid 37324251)
35. Okazaki T, Ebihara S, Asada M, et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia. 2008 10 : 932 939.
36. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004 126 : 1302 1311.
37. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003 98 : 2491 2499. (Pubitemid 37448762)
38. Younossi ZM, Nader FH, Bai C, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008 15 : 370 378. (Pubitemid 351473630)
39. Gish RG, Arora S, Reddy KR, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007 47 : 51 9. (Pubitemid 46817694)
40. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006 44 : 1598 1606.
41. Kugelmas M, Mah'moud MA. Do growth factors improve SVR in chronic HCV-genotype 1 patients treated with peg-Interferon and ribavirin? 59th Annual Meeting of the American Association for the Study of Liver Diseases, 31 October - 4 November, 2008, San Francisco, California [Abstract 209].
42. Lebray P, Nalpas B, Vallet-Pichard A, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir Ther 2005 10 : 769 776. (Pubitemid 41376857)
43. Edwards SW. Biochemistry and Physiology of the Neutrophil. Cambridge University Press
44. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006 354 : 2034 2045.
45. Wong S, Kaita K, Gauthier T, et al. A comparative trial of recombinant interferon alpha 2A versus alpha 2 beta on myelosuppression in healthy adult volunteers. Hepatogastroenterology 1996 43 : 301 305. (Pubitemid 26083803)
46. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003 37 : 533 541. (Pubitemid 37011777)
47. Durante-Mangoni E, Iardino P, Utili R, et al. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts. Antivir Ther 2006 11 : 637 640. (Pubitemid 44277429)
48. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002 36 : 1273 1279. (Pubitemid 35253446)
49. Juarez-Navarro A, Vera-de-León L, Navarro JM, et al. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 2005 27 : 317 322. (Pubitemid 41044273)
50. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003 124 : 1711 1719. (Pubitemid 36617688)
51. Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 2009 101 : S6 10.
52. Palmblad J, Andrès E, Maloisel F. Drug-induced neutropenias: all are not alike. Arch Intern Med 2002 162 : 1311 1312.
53. Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007 14 : 782 787. (Pubitemid 47561582)
54. Sallée M, Crétel E, Jean R, et al. Thrombotic thrombocytopenic purpura complicating interferon therapy in chronic C hepatitis. Gastroenterol Clin Biol 2008 32 : 145 146. (Pubitemid 351635692)
55. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007 357 : 2227 2236. (Pubitemid 350190753)